**Supplemental Table 1.** Hypothalamic-Pituitary-Adrenal Axis Activity, Inflammation Markers, Brain-Derived Neurotrophic Factor (*Bdnf*) mRNA Levels,and Behavioral Evaluations in F0 Rats.

|  |  |
| --- | --- |
| Measured variables | The results of the statistical analyses |
| Acute serum corticosterone (fig. 2A) | F(3,20) = 12.23, *P* < .001 |
| Acute serum interleukin-1β (fig. 2B) | F(3,20) = 25.94, *P* < .001 |
| Acute serum interleukin-6 (fig. 2C) | F(3,20) = 77.23, *P* < .001 |
| Acute expression of ionized calcium binding adaptor 1 (fig. 2D,E) | F(3,428) = 201.36, *P* < .001 |
| Resting serum corticosterone (fig. 3A) | F(3,25) = 13.93, *P* < .001 |
| Total serum corticosterone during physical restraint (area under the curve) (fig. 3B) | F(3,25) = 11.61, *P* < .001 |
| Respective levels of corticosterone during physical restraint (fig. 3C) | F(3,75) = 12.03, *P* < .001 (treatment) |
| F(3,75) = 562.75, *P* < .001 (time) |
| F(9,75) = 6.85, *P* < .001 (treatment × time interaction) |
| Hypothalamic *Crh* Mrna (fig. 3D) | F(3,20) = 7.11, *P* = .002 |
| Hippocampal *Crh* mRNA (fig. 3E) | F(3,20) = .50, *P* = .689 |
| Hypothalamic *Nr3c1* mRNA (fig. 3F) | F(3,20) = 5.53, *P* = .006 |
| Hippocampal *Nr3c1* mRNA (fig. 3G) | F(3,20) = 9.79, *P* < .001 |
| Hypothalamic *Nr3c2* mRNA (fig. 3H) | F(3,20) = 6.39, *P* = .003 |
| Hippocampal *Nr3c2* mRNA (fig. 3I) | F(3,20) = 12.14, *P* < .001 |
| Serum interleukin-1β (fig. 3J) | F(3,28) = 16.72, *P* < .001 |
| Serum interleukin-6 (fig. 3K) | F(3,28) = 25.35, *P* < .001 |
| Hypothalamic *Bdnf* mRNA (fig. 3L) | F(3,20) = 10.71, *P* < .001 |
| Hippocampal *Bdnf* mRNA (fig. 3M) | F(3,20) = 5.14, *P* = .009 |
| Time spent in open arms of elevated plus maze (fig. 4A) | F(3,68) = 11.44, *P* < .001 |
| Entries to open arms of elevated plus maze (fig. 4B) | F(3,68) = 5.49, *P* = .002 |
| Total distance during elevated plus maze (fig. 4C) | F(3,68) = 1.08, *P* = .363 |
| Prepulse inhibition of acoustic startle response (fig. 4D) | F(3,134) = 5.13, *P* = .003 (treatment) |
| F(2,134) = 130.63, *P* < .001(prepulse intensity) |
| F(6,134) = 1.27, *P* = .276 (treatment × prepulse intensity interaction) |
| Escape latency of Morris water maze (fig. 4E) | F(3,272) = .38, *P* = .768 (treatment) |
| F(4,272) = 140.04, *P* < .001 (day of training) |
| F(12,272) = .83, *P* = .615 (treatment × day of training interaction) |
| Crossing times over the platform of Morris water maze (fig. 4F) | F(3,69) = 6.89, *P* < .001 |
| Time spent in each quadrant of Morris water maze (fig. 4G,H) | F(3,204) = .39, *P* = .758 (treatment) |
| F(3,204) = 43.11, *P* <.001 (quadrant) |
| F(9,204) = 3.38, *P* <.001 (treatment × quadrant interaction) |

mRNA: messenger RNA; *Crh:* Corticotropin-releasing hormone; *Nr3c1:* glucocorticoid receptor; *Nr3c2:* Mineralocorticoid receptor; *Bdnf*: Brain-derived neurotrophic factor.